BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study | Zendy

Rossella Elisei | Zendy; Clara Ugolini | Zendy; David Viola | Zendy; Cristiana Lupi | Zendy; Agnese Biagini | Zendy; Riccardo Giannini | Zendy; Cristina Romei | Zendy; Paolo Miccoli | Zendy; Aldo Pinchera | Zendy; Fulvio Basolo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

Author(s) -

Rossella Elisei,

Clara Ugolini,

David Viola,

Cristiana Lupi,

Agnese Biagini,

Riccardo Giannini,

Cristina Romei,

Paolo Miccoli,

Aldo Pinchera,

Fulvio Basolo

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2008-0607

Subject(s) - medicine , thyroid carcinoma , mutation , univariate analysis , gastroenterology , multivariate analysis , oncology , stage (stratigraphy) , lymph node , pathology , thyroid , biology , gene , genetics , paleontology

The BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAF(V600E) mutation as a poor prognostic factor has been controversially reported in series with short-term follow-ups. In this study we verified the prognostic value of the BRAF(V600E) mutation in PTC patients with a long-term follow-up.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research